NEURO THERAPIA
NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can ... treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016.
NEURO THERAPIA
Social Links:
Industry:
Health Care Neuroscience Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Ohio, Illinois, United States
Country:
United States
Website Url:
http://www.neurotherapia.com
Total Employee:
1+
Status:
Active
Contact:
(216)870-7969
Email Addresses:
[email protected]
Total Funding:
11.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network Euro Wix
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arvinas
Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Employees Featured
Founder
Investors List
Cleveland Clinic
Cleveland Clinic investment in Series A - Neuro Therapia
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Series A - Neuro Therapia
Dolby Family Ventures
Dolby Family Ventures investment in Series A - Neuro Therapia
Brain Trust Accelerator Fund
Brain Trust Accelerator Fund investment in Series A - Neuro Therapia
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Seed Round - Neuro Therapia
Official Site Inspections
http://www.neurotherapia.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Neuro Therapia"
Alzheimer's Disease | NeuroTherapia, Inc. | United States
NeuroTherapia is developing oral, small molecule therapeutics that inhibit microglia cells, which are known to express proteins that drive inflammation in the CNS. We believe our therapies …See details»
Alzheimer's Disease | NeuroTherapia, Inc. | United States
NeuroTherapia is a clinical stage company developing new treatments for neuroinflammatory disorders. Neuroinflammation has now been recognized to play a key role in a range of neurologic disorders such as Alzheimer’s disease …See details»
Alzheimer's Disease | NeuroTherapia, Inc. | United States
NeuroTherapia home, drug discovery and research for neuropathic pain, Alzheimer's Disease, ALS, dementia and neuroinflammationSee details»
NeuroTherapia, Inc. | Alzheimer's Drug Discovery Foundation
Aug 8, 2023 · NeuroTherapia is developing a novel small molecule, NTRX-07, that binds selectively to activated microglia and restores their physiological activity, thereby inhibiting …See details»
NeuroTherapia, Inc. | Alzheimer's Drug Discovery Foundation
NeuroTherapia is developing NTRX-07 (previously identified as MDA7) for the treatment of Alzheimer's disease. There is currently no effective treatment for Alzheimer's disease (AD).See details»
Neuro Therapia - Crunchbase Company Profile
Contact Email [email protected] Phone Number (216)870-7969 NeuroTherpia develop new therapies for diseases with an underlying component of neuroinflammation.See details»
NeuroTherapia Raises $12.3M in the First Close of its Series B …
Aug 6, 2024 · NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations portfolio company focused on developing therapies for neurodegenerative diseases, …See details»
$1.7 Million Grant Supports Promising Drug That Targets …
Sep 21, 2016 · NeuroTherapia, Inc. has received a $1.7 million commitment from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance its drug NTRX-07 toward human clinical trials. …See details»
NeuroTherapia Receives Grant from Alzheimer's …
May 8, 2024 · The grant from the Alzheimer's Association will help fund the clinical development of NTRX-07, which has shown promising results in preclinical studies and in a small cohort of AD subjects in a...See details»
NeuroTherapia Raises $12.3M in the First Close of its Series B ...
Aug 7, 2024 · NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous …See details»
About | NeuroTherapia, Inc.
NeuroTherapia, Inc, a Delaware C-corporation was founded in 2015 by the Cleveland Clinic and two of its physician scientists. The Company is developing new drugs to treat diseases related …See details»
Encouraging Safety Data for Investigational NTRX-07 Therapy for ...
Oct 31, 2023 · In a phase 1b clinical trial, short-term treatment with NTRX-07 (NeuroTherapia, Cleveland, Ohio), an investigational small molecule targeting the cannabinoid type 2 (CB2) …See details»
NeuroTherapia Presents Clinical Data from Phase 1b Clinical Trial …
Oct 24, 2023 · Data from the study demonstrated a favorable safety profile at all dose ranges, a pharmacokinetic (PK) profile consistent with preclinical studies and in line with levels expected …See details»
About - NeuroTherapia, Inc.
NeuroTherpia, Inc., founded in 2015 by Cleveland Clinic Innovations based on research by Drs. Mohamed Naguib and Joseph Foss, on new therapies for diseases with an underlying …See details»
NeuroVoices: Joseph Foss, MD, on NTRX-07 and CBR2-Targeting …
Nov 8, 2023 · Joseph Foss, MD: NeuroTherapia is a company working on developing new small molecules targeted at neuroinflammation, which we believe plays an essential role in …See details»
NeuroTherapia Raises $12.3M in the First Close of its Series B …
CLEVELAND, Aug. 6, 2024 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations portfolio company focused on developing therapies for …See details»
About | NeuroTherapia, Inc.
Dec 1, 2020 · CLEVELAND, Aug. 6, 2024 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations portfolio company focused on developing therapies …See details»
NeuroTherapia Raises $12.3M in the First Close of its Series B …
Aug 6, 2024 · NeuroTherapia is a clinical-stage, privately held biotechnology company developing oral, small-molecule drugs to address neuro-inflammatory conditions of the central nervous …See details»
NeuroTherapia raises $12.3m to advance inflammation-targeting …
Aug 7, 2024 · US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an …See details»
About | NeuroTherapia, Inc.
In preclinical studies we have shown that NTRX-07 reduces microglial activity, leading to reductions in neuroinflammation, while also helping promote clearance of amyloid β. …See details»